FXR/TGR5 Dual Agonist INT-767 Reduces NAS & Fibrosis & Improves Plasma & Hepatic Lipid Profiles in the AMLN Mouse Model of Diet-induced & Biopsy-confirmed NASH

被引：0

作者：

Roth, Jonathan ^{[1
]}

Feigh, Michael ^{[2
]}

Herrmann, Sibylle ^{[3
]}

机构：

[1] Intercept Pharmaceut Inc, San Diego, CA USA

[2] Gubra, Horsholm, Denmark

[3] Intercept Pharma Europe, London, England

来源：

SWISS MEDICAL WEEKLY | 2017年 / 147卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PH4

引用

页码：20S / 20S

页数：1

共 40 条

[21] HEPATOPROTECTIVE EFFECTS OF SEMAGLUTIDE IN THE GAN DIET-INDUCED OBESE AND BIOPSY-CONFIRMED MOUSE MODEL OF NASH WITH ADVANCED FIBROSIS AND HEPATOCELLULAR CARCINOMA
Heimburger, Sebastian Moller Nguyen
Nielsen, Malte H.
Mollerhoj, Mathias Bonde
Oro, Denise
Madsen, Martin R.
Vyberg, Mogens
Hansen, Henrik H.
Feigh, Michael
GASTROENTEROLOGY, 2023, 164 (06) : S1262 - S1262
[22] Hepatic effects of NS-0200 (Leucine-Metformin-Sildenafil) in an obese mouse model of diet-induced and biopsy-confirmed NASH
Zemel, M.
Flores, O.
Rigbolt, K.
Illemann, M.
Petersen, P. S.
Feigh, M.
JOURNAL OF HEPATOLOGY, 2018, 68 : S348 - S348
[23] Semaglutide Reduces Tumor Burden in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH with Advanced Fibrosis and HCC
Feigh, Michael
Tozzi, Marco
Hansen, Henrik H.
DIABETES, 2024, 73
[24] Differential hepatoprotective effects of semaglutide and lanifibranor in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC
Nielsen, Malte H.
Pors, Susanne
Nohr-Meldgaard, Jacob
Madsen, Andreas Nygaard
Mollerhoj, Mathias Bonde
Oro, Denise
Vyberg, Mogens
Hansen, Henrik B.
Feigh, Michael
JOURNAL OF HEPATOLOGY, 2023, 78 : S530 - S531
[25] MET409, a Potent, Non-Bile Acid Sustained FXR Agonist, Shows Rapid Disease Reversal in a Diet-Induced Obese Mouse Model of Biopsy-Confirmed Nash
Wagner, Brandee
Govek, Steve
Nagasawa, Johnny
Douglas, Karensa
Dedman, Harty
Milik, Angelica
Lee, Kyoung-Jin
Ortiz, Alvaro
Qian, Jing
Lu, Nhin
Liu, Xueqing
Bischoff, Eric
Voldem-Clausen, Kristoffer
Veidal, Sanne
Feigh, Michael
Song, Ken
Smith, Nick
HEPATOLOGY, 2018, 68 : 1006A - 1006A
[26] M480, a novel non-bile acid FXR agonist, shows improvement across multiple parameters in a diet-induced obese mouse model with biopsy-confirmed NASH
Wagner, B.
Brigham, D.
Lee, K. -J.
Ortiz, A.
Lu, N.
Douglas, K.
Govek, S.
Feigh, M.
Veidal, S.
Vrang, N.
Song, K.
Smith, N.
Dedman, H.
Milik, A.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S433 - S433
[27] Dual Farnesoid X Receptor/TGR5 Agonist INT-767 Reduces Liver Injury in the Mdr2-/- (Abcb4-/-) Mouse Cholangiopathy Model by Promoting Biliary HCO3- Output
Baghdasaryan, Anna
Claudel, Thierry
Gumhold, Judith
Silbert, Dagmar
Adorini, Luciano
Roda, Aldo
Vecchiotti, Stefania
Gonzalez, Frank J.
Schoonjans, Kristina
Strazzabosco, Mario
Fickert, Peter
Trauner, Michael
HEPATOLOGY, 2011, 54 (04) : 1303 - 1312
[28] The GLP-1 analogue, liraglutide, reduces NAFLD Activity Score and Fibrosis Stage and improves metabolic parameters in a diet-induced obese mouse model of biopsy-confirmed nonalcoholic steatohepatitis (NASH)
Tolbol, Kirstine S.
Veidal, Sanne Skovgaard
Knudsen, Sanne M.
Erichsen, Helle K.
Kristiansen, Maria N.
Jelsing, Jacob
Vrang, Niels
Feigh, Michael
HEPATOLOGY, 2016, 64 : 782A - 782A
[29] ZGN-1061 improves metabolic parameters and hepatic pathology in an obese mouse model of diet-induced and biopsy-confirmed nonalcoholic steatohepatitis
Vath, J. E.
Illemann, M.
Veidal, S. S.
Feigh, M.
Burkey, B. F.
Hughes, T. E.
DIABETOLOGIA, 2018, 61 : S326 - S327
[30] ZGN-1061 Improves Metabolic Parameters and Hepatic Pathology in an Obese Mouse Model of Diet-Induced and Biopsy-Confirmed Nonalcoholic Steatohepatitis
Burkey, Bryan F.
Illemann, Martin
Veidal, Sanne
Feigh, Michael
Vath, James
Hughes, Thomas E.
DIABETES, 2018, 67

← 1 2 3 4 →